<DOC>
	<DOCNO>NCT00496470</DOCNO>
	<brief_summary>The purpose study investigate effect combine treatment Symbicort Spiriva , term improvement lung function , symptom inflammatory marker , patient severe COPD .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Symbicort® add-on Treatment Spiriva® Patients With Severe COPD .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>&gt; =40 year age , diagnose COPD symptom &gt; =2 year , prebronchodilatory FEV1 &lt; =50 % PN Current respiratory tract disorder COPD , history asthma rhinitis , significant unstable cardiovascular disorder</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease , COPD</keyword>
</DOC>